However, the long-term usage of the inhibitors of mTORC1 increases interleukin-6 (IL-6) production, activates the signal transducer and activator of transcription 3 (STAT3), and facilitates HCC development in a murine obesity liver model [38]. The gene discussed is STAT3; the disease is hepatocellular carcinoma.